Recent press coverage of our work to develop healthspan-extending drugs recognises their potential to offer “a more sustainable path to healthier, longer lives”

Istesso’s groundbreaking work to develop mitochondria-modulating drugs to repair and regenerate human tissue has huge potential to extend human healthspan. The possible application of these drugs to treat a range of age-related diseases, including muscle loss, rheumatoid arthritis, pulmonary fibrosis and osteoporosis is attracting the attention of journalists too.

In an article published in Forward Magazine – a biannual publication celebrating the best of innovation and exploration by IP firm Mewburn Ellis – journalist Charles Orton-Jones acknowledges that research into tissue regeneration is “still in its infancy”. However, reflecting on our pioneering research and the results of a recent clinical study showing that our lead drug Leramistat elicited tissue repair in models of autoimmune and fibrotic disease, he writes, “The promise of mitochondria to stimulate repair in hard-to-treat diseases is formidable. The early results are dramatic. Tissue regeneration holds the promise of not merely treating intractable conditions such as fibrosis and muscle wasting, but reversing their course.”

In an article published on Longevity Technology, a website focussed on the longevity sector, journalist Eleanor Garth is similarly enthused, writing: “Istesso’s strategy, blending metabolic insight with tissue engineering ambitions, taps into a current of longevity science that is gaining momentum: that aging is, in part, the erosion of repair. Rekindling that repair, not with cells or implants or gene edits, but with an oral drug that leverages the body’s own systems, might just offer a more sustainable path to healthier, longer lives.”